Previous close | N/A |
YTD return | N/A |
Expense ratio (net) | N/A |
Category | N/A |
Last cap gain | N/A |
Morningstar rating | N/A |
Morningstar risk rating | N/A |
Sustainability rating | N/A |
Net assets | N/A |
Beta (5Y monthly) | N/A |
Yield | N/A |
5y average return | N/A |
Holdings turnover | N/A |
Last dividend | N/A |
Average for category | N/A |
Inception date | N/A |
It might be of some concern to shareholders to see the Frontline Ltd. ( NYSE:FRO ) share price down 10% in the last...
Five abstracts accepted with new research and technology insights and data to further enhance AAV-based gene therapy candidatesLONDON, May 02, 2022 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) (the “Company” or “Freeline”) today announced the upcoming presentation of five posters at the 25th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT) that will take place May 16-19, 2022 in Washington, D.C. The presentations will provide new insights and data
Frontline Ltd. (“Frontline” or “the Company”) announces that Mr. Tor Svelland has resigned as a Director of the Company. Mr. Svelland has served as a Director since August 2020. The Board would like to thank Mr. Svelland for his contribution and wishes him well in his future pursuits. Frontline announces the appointment of Mr. Ole B. Hjertaker as a Director of the Company. Ole B. Hjertaker has been a Director of SFL Corporation Ltd. (“SFL”) since October 2019. Mr. Hjertaker has served as Chief E